Accelerate Your COVID-19 Diagnostic Product Development From Concept To Market Launch

During a global pandemic, speed to market is more important than ever. At Ximedica, we have the breadth of services and relevant experience needed to accelerate the development and launch of COVID-19 / SARS-CoV-2 projects.

See how we helped develop LexaGene’s PCR-based MiQLab™ fully automated diagnostic system for quick response to COVID-19 IVD needs and to prepare for Emergency Use Authorization.

Download Now

How Ximedica Can Help?

As a fully integrated design and development firm specializing in medical diagnostics and technologies, we deliver all the expertise you need to move your COVID-19 / SARS-CoV-2 testing solutions quickly to market – all under one roof. Because of our focused experience in this space, we’re currently working with dozens of companies to translate their novel COVID-19 detection ideas into custom instrumentation or complex consumables ready to meet key milestones to support fundraising efforts or be launched into the IVD-regulated market. To learn how Ximedica’s services can help accelerate your COVID-19 / SARS-CoV-2 Dx solutions, please contact us.

End-to-end services under one roof

Concept generation, design and human factors, prototyping, detailed engineering, pilot manufacturing

In-house regulatory services

Support filing for FDA EUA or 510k submissions

Excellence in instrument and consumable design

Microfluidics, reagent integration, thermal and optical systems, digital infrastructure

Strong molecular diagnostics expertise

Sample prep automation, PCR, and LAMP amplification

Multi generational planning

Targeting Minimum Viable Product (MVP) launch and next versions

Pilot manufacturing capabilities

Design for manufacturability, robust supply chain, seamless transfer to large-volume manufacturer

What We’re Working On: Diverse Solutions Targeting COVID-19

We’re currently working with numerous leading global diagnostic firms and early-stage companies on multiple COVID-19 / SARS-CoV-2 projects. Below are just a few of our current technology development efforts.

LexaGene’s MiQLab™, PCR-based, fully automated diagnostic system for quick response to COVID-19 IVD needs.

Instrument-free, one-step, Lateral Flow Assay (LFA) diagnostics kits for SARS-CoV-2.

Rapid, quantitative, point-of-care platform for IVD detection and diagnosis of COVID-19.

CLIA-waived, point-of-care PCR analyzer targeting multiple pathogen genes simultaneously.

Lab-based, real-time, PCR detection system for COVID-19 identification.

Handheld sample-to-answer molecular system for infectious disease detection.

Instrument-free saliva sample collection tube for detection of SARS-CoV-2.

What We Do

With over 30 years of experience in medical device design and development, we’re here to create exceptional healthcare technologies that improve outcomes, enhance lives, and successfully advance our clients' business strategies.